Cardiac and renal complications of carfilzomib in patients with multiple myeloma

Clinical trials with carfilzomib have indicated a low but reproducible incidence of cardiovascular and renal toxicities. Among 60 consecutive myeloma patients treated with carfilzomib-based regimens who were thoroughly evaluated for cardiovascular risk factors, 12% (95% confidence interval, 3.8%-20%...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Adv
Autori principali: Dimopoulos, Meletios A., Roussou, Maria, Gavriatopoulou, Maria, Psimenou, Erasmia, Ziogas, Dimitrios, Eleutherakis-Papaiakovou, Evangelos, Fotiou, Despina, Migkou, Magdalini, Kanellias, Nikolaos, Panagiotidis, Ioannis, Ntalianis, Argyrios, Papadopoulou, Elektra, Stamatelopoulos, Kimon, Manios, Efstathios, Pamboukas, Constantinos, Kontogiannis, Sofoklis, Terpos, Evangelos, Kastritis, Efstathios
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2017
Soggetti:
Lymphoid Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5738981/
https://ncbi.nlm.nih.gov/pubmed/29296960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016003269
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi